We reiterate our Neutral recommendation on Genomic Health (NASDAQ:GHDX) following its first-quarter 2011 results, with both revenue and earnings sailing past the corresponding Zacks Consensus Estimates.
While Genomic currently has two products in its portfolio, Oncotype DX breast and Oncotype DX colon cancer tests, the latter has yet to make any significant contribution to the top line. Banking on its several strategies directed toward an increasing acceptance of the Oncotype DX test, Genomic is … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards